PCVXVaxcyte, Inc.vs its industry peers
A metric-by-metric comparison of Vaxcyte, Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCVXEsta | $9.2B#6 | — | 3.3x#1 | — | — | -65.2%#6 | — | -0.0%#2 | — | — | — | — |
| MRNA | $88.5B#1 | — | 13.1x#4 | 45.5x#3 | -39.9%#4 | 20.8%#3 | -158.1%#3 | -41.7%#6 | -54.6%#3 | — | — | — |
| TWST | $9.6B#5 | — | 21.5x#6 | 25.4x#1 | 20.3%#2 | 62.8%#1 | -36.2%#2 | -17.4%#5 | -41.4%#2 | — | — | — |
| ORKA | $6.4B#7 | — | 5.8x#2 | — | — | -25.9%#5 | — | -9.5%#3 | — | — | 245.4%#1 | — |
| KYMR | $10.8B#4 | — | 6.7x#3 | 275.9x#4 | -16.7%#3 | 39.1%#2 | -891.1%#4 | 19.3%#1 | — | — | 106.3%#2 | — |
| RVMD | $41.0B#3 | — | 15.7x#5 | — | — | -88.5%#7 | — | -43.4%#7 | — | — | — | — |
| NTRA | $59.7B#2 | — | 32.8x#7 | 25.9x#2 | 35.9%#1 | -9.3%#4 | -13.4%#1 | -11.4%#4 | -18.0%#1 | — | — | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice